本文選題：烏苯美司　切入點(diǎn)：惡性腫瘤　出處：《中國(guó)藥房》2017年24期

【摘要】：目的:系統(tǒng)評(píng)價(jià)烏苯美司聯(lián)合化療用于惡性腫瘤的療效和安全性,為臨床提供循證參考。方法:計(jì)算機(jī)檢索Central、PubMed、相關(guān)期刊論文、中文科技期刊數(shù)據(jù)庫(kù)、萬(wàn)方數(shù)據(jù)庫(kù),收集烏苯美司聯(lián)合化療(試驗(yàn)組)對(duì)比單純化療(對(duì)照組)用于惡性腫瘤的隨機(jī)對(duì)照試驗(yàn)(RCT),篩選文獻(xiàn)、提取資料并采用Cochrane系統(tǒng)評(píng)價(jià)員手冊(cè)5.1.0提供的偏倚風(fēng)險(xiǎn)評(píng)價(jià)標(biāo)準(zhǔn)評(píng)價(jià)納入研究質(zhì)量,采用Rev Man 5.3統(tǒng)計(jì)軟件進(jìn)行Meta分析。結(jié)果:共納入12項(xiàng)RCT,包括762例患者。Meta分析結(jié)果顯示,試驗(yàn)組患者近期有效率[RR=1.24,95%CI(1.08,1.43),P=0.002]、生存質(zhì)量(KPS)評(píng)分改善率[RR=1.69,95%CI(1.46,1.95),P0.001]顯著高于對(duì)照組,胃腸道毒性發(fā)生率[RR=0.74,95%CI(0.57,0.94),P=0.02]和白細(xì)胞抑制發(fā)生率[Ⅰ°～Ⅳ°(用藥≤3個(gè)月):RR=0.54,95%CI(0.37,0.79),P=0.002;Ⅲ°～Ⅳ°:RR=0.44,95%CI(0.29,0.68),P0.001]顯著低于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義。結(jié)論:烏苯美司聯(lián)合化療用于惡性腫瘤,可以提高患者的近期療效,改善生存質(zhì)量,降低胃腸道毒性和骨髓毒性。
[Abstract]:Objective: to evaluate the efficacy and safety of Ubenemethasone combined chemotherapy for malignant tumors and to provide evidence based reference for clinical application. Methods: a computer-based search of Centralus PubMed, Chinese Journal Full-text Database, Chinese Sci-tech Journal Database and Wanfang Database was carried out. A randomized controlled trial of Ubenemethasone combined with chemotherapy (trial group) for malignant tumors was collected and the literature was screened. The data were extracted and the bias risk evaluation criteria provided by the Cochrane system evaluator manual 5.1.0 were used to evaluate the quality of the study. The Meta analysis was carried out with Rev Man 5.3 statistical software. Results: a total of 12 RCTs were included, including 762 patients. The short-term effective rate [RRN 1.2495 CII 1.081.43 P0.002], the improvement rate of quality of life score (RRR1.6995 CI1.461.95CI1.461.95P0.001), the incidence of gastrointestinal toxicity (RR0.7495CI0.570.94FU P0.02) and the incidence of leukocyte inhibition [鈪，

本文編號(hào)：1656232